FDA Approves Tibsovo for Adjuvant Treatment of IDH1-Mutated Cholangiocarcinoma

The FDA approved ivosidenib (Tibsovo, Servier) for adults with previously treated, locally advanced or metastatic ...

AUGUST 30, 2021